Before Southern California biotech startup BCN Biosciences became engaged with a new program at the National Institutes of Health (NIH), the firm thought it had one indication for its experimental small molecule BCN057 (YEL002) – radiation mitigation.
The company also thought it was targeting the appropriate customers – radiation and medical oncologists – and would need at...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

